PROVIDENCE, Rhode Island, July 6, 2026
Nabsys 2.0, LLC, a pioneer in electronic genome mapping (EGM) technology, has appointed renowned genomics expert Alka Chaubey, Ph.D., FACMG, as its inaugural Chief Medical and Genomics Officer, marking a significant milestone in the company’s strategy to accelerate the global adoption of high-resolution structural variant analysis. Effective July 6, 2026, Dr. Chaubey will lead medical and scientific affairs, strengthen collaborations with leading researchers and clinical experts, and support the expansion of the company’s OhmX™ Electronic Genome Mapping Platform across research and translational medicine. Widely recognized as one of the pioneers in clinical genome mapping, Dr. Chaubey brings more than 20 years of expertise in molecular genetics, cytogenomics, molecular diagnostics, and structural variant analysis, positioning Nabsys to accelerate the development of next-generation genomic technologies capable of transforming biomedical research and future clinical applications. The appointment reflects the growing importance of advanced genome mapping technologies in identifying structural genomic variants that are often overlooked by conventional sequencing methods, supporting breakthroughs in precision medicine and genetic disease research.
Genome Mapping Pioneer to Accelerate Electronic Genome Mapping Innovation
As Nabsys’ first Chief Medical and Genomics Officer, Dr. Chaubey will play a central role in advancing scientific collaborations, expanding laboratory adoption, and guiding clinical validation strategies for the OhmX™ Electronic Genome Mapping Platform. The proprietary platform combines precision electronics, nanofluidics, and computational biology to deliver high-resolution structural variation analysis, enabling researchers to identify complex genomic alterations with exceptional accuracy. Company leadership believes her extensive experience in clinical-grade assay development, regulatory compliance, and laboratory implementation will accelerate the transition of electronic genome mapping from advanced research laboratories into broader translational and future clinical applications.
Nabsys aims to improve accessibility to genome mapping by providing scalable technologies capable of supporting laboratories of all sizes while enabling deeper biological insights into structural genomic variation associated with inherited disorders, cancer, and other complex diseases. The appointment also reinforces the company’s long-term commitment to making advanced genome analysis more widely available to the global genomics research community.
Extensive Genomics Leadership Strengthens Nabsys Scientific Strategy
Advertisement
Dr. Chaubey joins Nabsys following an accomplished career spanning leadership positions across the genomics industry. Most recently serving as Chief Medical Officer at Bionano Genomics, she played a leading role in advancing the adoption of Optical Genome Mapping (OGM) through scientific collaborations, clinical validation studies, and numerous peer-reviewed publications. Earlier, she served as Head of Cytogenomics at PerkinElmer Genomics, where she led the development and commercialization of multiple innovative genomic testing platforms, including low-pass whole-genome sequencing assays, non-invasive prenatal testing (NIPT) solutions, and advanced assays for facioscapulohumeral muscular dystrophy.
She also directed cytogenomics laboratories and currently maintains several academic appointments supporting molecular diagnostics and genomic medicine. Throughout her career, Dr. Chaubey has authored or co-authored more than 100 scientific publications, abstracts, and book chapters, while contributing to professional organizations including the American College of Medical Genetics and Genomics, Association for Molecular Pathology, and the College of American Pathologists. Her expertise in CLIA- and CAP-regulated laboratory environments further strengthens Nabsys’ efforts to develop clinically validated genome mapping workflows.
OhmX Platform Advances the Future of Precision Genomics Research
The appointment comes as Nabsys continues expanding the capabilities of its research-use-only OhmX™ Platform, which is commercially available to laboratories worldwide. The company’s proprietary Electronic Genome Mapping (EGM) technology provides comprehensive analysis of structural genomic variants, addressing limitations associated with conventional sequencing and cytogenetic methods. By combining innovative engineering with advanced computational biology, the platform enables researchers to study genome architecture with enhanced resolution, supporting applications in cytogenetics, molecular genetics, cell and gene therapy research, and precision medicine. Supported by its strategic partnership with Hitachi High-Tech, Nabsys is well positioned to accelerate commercial adoption while driving future innovation in genome mapping technologies. As demand for advanced genomic tools continues to grow, the appointment of Dr. Alka Chaubey further reinforces the company’s commitment to delivering scalable, high-performance solutions that expand scientific understanding of complex genomic variation and contribute to the future of precision healthcare.
Source: Nabsys press release
